Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

59.01
+1.151.99%
Post-market: 59.010.00000.00%19:30 EDT
Volume:609.97K
Turnover:35.80M
Market Cap:4.32B
PE:-35.22
High:60.55
Open:58.36
Low:57.36
Close:57.86
52wk High:62.32
52wk Low:14.79
Shares:73.27M
Float Shares:61.73M
Volume Ratio:0.74
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6753
EPS(LYR):-1.8300
ROE:-15.31%
ROA:-11.00%
PB:4.83
PE(LYR):-32.25

Loading ...

Enliven Therapeutics to Present Phase 1 Enable Trial Data for ELVN-001 in CP-CML at SOHO 2026

Reuters
·
Sep 01

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (Soho) 2026 Annual Meeting

THOMSON REUTERS
·
Sep 01

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

TIPRANKS
·
Aug 24

Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17

Reuters
·
Aug 20

Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62

THOMSON REUTERS
·
Aug 18

Enliven initiated with an Outperform at William Blair

TIPRANKS
·
Aug 18

Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating

THOMSON REUTERS
·
Aug 18

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Aug 13

Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares

Reuters
·
Aug 07

Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)

TIPRANKS
·
Aug 06

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06

Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 06

Enliven Therapeutics, Inc. : Jefferies Raises Target Price to $69 from $59

THOMSON REUTERS
·
Aug 06

Enliven Therapeutics, Inc. : Guggenheim Cuts Target Price to $78 from $80

THOMSON REUTERS
·
Aug 06

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Enliven Net Loss Widens 28.2% to $32.5 Million in Q2 FY26

Reuters
·
Aug 06

Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 262,213 in Common Shares

Reuters
·
Jul 22

13D Filings

Dow Jones
·
Jul 11

Enliven price target raised to $65 from $56 at H.C. Wainwright

TIPRANKS
·
Jul 09